Author

M. Treur

Observed names: M Treur, M. J. TREUR, M. J. Treur, M.J. Treur, MJ Treur, Maarten J. Treur, Maarten Jacob Treur, Maarten Treur, Treur Maarten, Treur, Maarten, Treur, Maarten J.

Observed institution: Pharmerit (Netherlands)

OpenAlex ID: A5108542558

Capsaicin 8% Patch Versus Oral Neuropathic Pain Medications for the Treatment of Painful Diabetic Peripheral Neuropathy: A Systematic Literature Review and Network Meta-analysis

2017 · Floortje van Nooten, Maarten Treur, et al. · Clinical Therapeutics · 122

Efficacy of recombinant activated factor VII vs. activated prothrombin complex concentrate for patients suffering from haemophilia complicated with inhibitors: a Bayesian meta‐regression

2009 · M. J. TREUR, F. MCCRACKEN, et al. · Haemophilia · 42

A pharmaco-economic analysis of patients with schizophrenia switching to generic risperidone involving a possible compliance loss

2009 · Maarten Treur, Bart Heeg, et al. · BMC Health Services Research · 32

PDF

A cost-effectiveness analysis of iStent inject combined with phacoemulsification cataract surgery in patients with mild-to-moderate open-angle glaucoma in France

2021 · Kaspar Nieland, Antoine Labbé, et al. · PLoS ONE · 28

PDF

Assessment of the Economic Impact of Belimumab for the Treatment of Systemic Lupus Erythematosus in the Italian Setting: A Cost-Effectiveness Analysis

2015 · Francesca Pierotti, Ilaria Palla, et al. · PLoS ONE · 27

Real-world Outcomes of Multiple Myeloma: Retrospective Analysis of the Czech Registry of Monoclonal Gammopathies

2018 · Roman Hájek, Jiri Jarkovsky, et al. · Clinical Lymphoma Myeloma & Leukemia · 24

Cost-effectiveness analysis of rivaroxaban for treatment and secondary prevention of venous thromboembolism in the Netherlands

2017 · Marieke Heisen, Maarten J. Treur, et al. · Journal of Medical Economics · 21

PDF

The cost-effectiveness of paliperidone extended release in Spain

2012 · M. Treur, E. Baca, et al. · Journal of Medical Economics · 20

A cost utility analysis of simeprevir used with peginterferon + ribavirin in the management of genotype 1 hepatitis C virus infection, from the perspective of the UK National Health Service

2015 · Kirsten Westerhout, Maarten Treur, et al. · Journal of Medical Economics · 19

PDF

Efficacy, tolerability, and safety of aripiprazole once-monthly versus other long-acting injectable antipsychotic therapies in the maintenance treatment of schizophrenia: a mixed treatment comparison of double-blind randomized clinical trials

2015 · Istvan M. Majer, Fiona Gaughran, et al. · Journal of Market Access & Health Policy · 15

PDF

Cost-effectiveness analysis of simeprevir in combination with peginterferon and ribavirin for treatment-naïve chronic hepatitis C genotype 1 patients in Japan

2015 · Hiroyo Kuwabara, Kirsten Westerhout, et al. · Journal of Medical Economics · 14

PDF

Cost-Effectiveness Analysis of Aripiprazole Augmentation Treatment of Patients with Major Depressive Disorder Compared to Olanzapine and Quetiapine Augmentation in Turkey: A Microsimulation Approach

2013 · Mete Saylan, M.J. Treur, et al. · Value in Health Regional Issues · 12

Fingolimod reduces direct medical costs compared to natalizumab in patients with relapsing–remitting multiple sclerosis in The Netherlands

2012 · M. Heisen, M. J. Treur, et al. · Journal of Medical Economics · 11

PDF

Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK.

2015 · Michael Tempest, Christophe Sapin, et al. · PubMed · 9

Estimating the quality-of-life impact and cost-effectiveness of alpha-blocker and anti-muscarinic combination treatment in men with lower urinary tract symptoms related to benign prostatic hyperplasia and overactive bladder

2012 · Bram G. Verheggen, Richard Lee, et al. · Journal of Medical Economics · 9

PDF

Predictors of Overall Survival (OS) in Patients with Multiple Myeloma (MM) Initiating First- and Second-Line Treatment in the Czech Republic

2016 · Roman Hájek, Jarkovsky Jiri, et al. · Blood · 5

Pharmacoeconomic Evaluation of Aripiprazole Once-Monthly Versus Paliperidone Palmitate in the UK: Findings From Qualify

2015 · M Tempest, C Sapin, et al. · Value in Health · 4

Cost-Effectiveness and Cost-Utility Analysis of Belimumab for the Treatment of Patients with Systemic Lupus Erythematosus in Portugal

2013 · M. Gouveia, M. Borges, et al. · Value in Health · 4

PDF

Optimal Treatment Sequencing In Multiple Myeloma: An Exploratory Modeling Approach

2010 · Bart Heeg, Michel van Agthoven, et al. · Blood · 4

Optimizing choice of oral interferon-free treatment for genotype 1 hepatitis C virus using testing for NS5A resistance: a cost-utility analysis from the perspective of the Italian National Health Service

2017 · Kirsten Westerhout, Walter Bouwmeester, et al. · ClinicoEconomics and Outcomes Research · 3

PDF

Long-Term Outcomes and Treatment Patterns in Patients with Symptomatic Multiple Myeloma in the Real-World Setting: A Retrospective Analysis of the Czech Rmg Registry

2016 · R Hájek, J Jarkovsky, et al. · Value in Health · 3

Treatment Sequencing Survival Model for Patients with Multiple Myeloma Ineligible for Stem Cell Transplantation (SCT)

2014 · B. Heeg, M. Van Agthoven, et al. · Value in Health · 3

Cost-effectiveness Analysis of Mirikizumab Versus Ustekinumab in Advanced Therapy Experienced Patients With Moderately to Severely Active Ulcerative Colitis in the Us

2024 · Xuan Wang, Lytske Bakker, et al. · Inflammatory Bowel Diseases · 2

PDF

A Systematic Literature Review And Network Meta-Analysis of Capsaicin 8% Patch Versus Oral Neuropathic Pain Medications for The Treatment of Painful Diabetic Peripheral Neuropathy

2015 · FE van Nooten, M Charokopou, et al. · Value in Health · 2

Cost-Utility Analysis of Simeprevir With Peginterferon + Ribavirin (SMV/PR) in the Management of Genotype 1 (G1) and 4 (G4) Hepatitis C Virus (HCV) Infection; from the Perspective of the Uk National Health Service (NHS)

2014 · K.Y. Westerhout, M. Treur, et al. · Value in Health · 2

Works count: 65

Citation count: 450

H-index: 12

I10-index: 13